Corporate Magazine 2012 - Boehringer Ingelheim

usiness year 2012 key aspects 2012Furthermore, the evaluation of the German Joint Federal Committe (G-BA) fortrajenta® means the setting of a reimbursement price on a level with genericsulphonylureas. This is unacceptable for a newly developed, innovative active ingredientin the DPP-4 inhibitor class.Consumer Health CareThe business area Consumer Health Care has grown again mainly in emergingmarkets and achieved worldwide sales of EUR 1,505 million, corresponding togrowth of + 7.8% compared to the previous year.BiopharmaceuticalsThe business area Biopharmaceuticals focuses on the development and productionof new, innovative biopharmaceuticals. It is comprised of the contract manufacturingbusiness, biosimilars and the research and development of new biologicalactive ingredients. Here, Boehringer Ingelheim achieved net sales amounting toEUR 549 million (+ 5.3%)Boehringer Ingelheim’s contract manufacturing business is now represented byour new brand Boehringer Ingelheim BioXcellence, which in the market standsfor excellence, quality and reliability. We want to further expand our position asthe world’s biggest producer of contract-manufactured biopharmaceuticals andoffer the whole production technology chain from DNA to fill and finish. Togetherwith our customers, we have in past few years brought a total of 22 biopharmaceuticalcompounds (or new biological entities – NBEs) to market. In addition, wehave decided to expand our current Biopharmaceuticals business to developingbiosimilars.Animal HealthThe products in our Animal Health business developed equally favourably, withtotal turnover of EUR 1,062 million (+ 8.8%), led by ingelvac circoflex®, a swinevaccine, with sales of EUR 279 million (+ 8,6%).Key aspects 201213